Jim Simons
IDXG

Jim Simons’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Jim Simons’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,642
Closed -$292K – 3511
2016
Q4 		$292K Sell
6,642
-209
-3% -$6.66K ﹤0.01% 2919
2016
Q3 		$110K Buy
6,851
+237
+4% +$6.55K ﹤0.01% 3169
2016
Q2 		$218K Buy
6,614
+29
+0.4% +$1.09K ﹤0.01% 3026
2016
Q1 		$184K Buy
6,585
+51
+0.8% +$1.36K ﹤0.01% 3111
2015
Q4 		$304K Sell
6,534
-19
-0.3% -$2.12K ﹤0.01% 2883
2015
Q3 		$1.17M Buy
6,553
+34
+0.5% +$6.7K ﹤0.01% 2303
2015
Q2 		$932K Sell
6,519
-7
-0.1% -$971 ﹤0.01% 2481
2015
Q1 		$881K Sell
6,526
-157
-2% -$25.7K ﹤0.01% 2372
2014
Q4 		$1.2M Buy
6,683
+1,207
+22% +$215K ﹤0.01% 2053
2014
Q3 		$1.31M Buy
5,476
+167
+3% +$55.8K ﹤0.01% 1896
2014
Q2 		$2.33M Buy
5,309
+52
+1% +$24K 0.01% 1650
2014
Q1 		$2.41M Sell
5,257
-52
-1% -$27K 0.01% 1667
2013
Q4 		$2.55M Buy
5,309
+14
+0.3% +$6.84K 0.01% 1613
2013
Q3 		$2.55M Buy
5,295
+21
+0.4% +$10.1K 0.01% 1542
2013
Q2 		$2.48M Buy
+5,274
New +$2.39M 0.01% 1469

Other funds holding IDXG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AS
Arxis Securities New York $18.7M AUM
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
TDC
Thompson Davis & Co Richmond, Virginia $167M AUM 33.45% 1-Year Est. Return

Jim Simons's IDXG Position: Q1 2017 in Review

Jim Simons sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2017, closing a stake of 6,642 shares — an estimated $292K sold.

Jim Simons first reported a position in IDXG in Q2 2013 and held it in 15 quarters. The position peaked at $2.55M in Q4 2013. 16 funds tracked by Wall St. Rank hold IDXG as of Q1 2017.

  • Jim Simons reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Jim Simons sold 6,642 Interpace Biosciences, Inc. Common Stock shares in Q1 2017, an estimated $292K.
  • Jim Simons first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 15 quarters.
  • Jim Simons's Interpace Biosciences, Inc. Common Stock position peaked at $2.55M in Q4 2013.
  • 16 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2017.

Based on Renaissance Technologies's 13F filing for Q1 2017, filed 12 May 2017.